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APPENDIX

has the lowest rate of prostate cancer mortality saw the largest
increase in PSA screening over this time period.2 Many other
theories have been formulated, but none help to determine this
unequal adoption of screening recommendations.
We look forward to future publications from this group and
others concerning why recommendations were accepted with such
heterogeneous results. With so many possible explanations, it’s
unlikely we will ever discover the true nature behind heterogeneity in adoption of screening recommendations. It is our role
as clinicians to be aware of the biases that exist in our community and region, and as always to treat our patients with evidence based techniques.
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EDITORIAL COMMENT
Following the United States Preventative Services Task Force
(USPSTF) recommendation against prostate specific antigen
(PSA) testing in 2011, we have seen many publications highlighting that utilization of PSA testing has decreased nationwide.1
The state-by-state analysis published here adds to the growing
literature that the USPSTF testing recommendations led to decreased PSA screening. However, the authors of this manuscript cleverly subset this into geography and determine that the
adoption of these guidelines isn’t uniform. In fact, it’s anything
but a simple story.
Like many things in medicine, there appear to be areas where
we find strong adopters of the recommendation (states like
Vermont), a few states who ignore the recommendations altogether and actually increase testing, and the vast majority of states
somewhere in between, with mild decreases in screening. The
real question with this observation is how do we understand these
trends? What’s driving this heterogeneity?
One theory is that communities most devastated by prostate
cancer would limit reductions in screening? Yet among states with
the highest mortality and prevalence, only Mississippi and Alabama
didn’t decrease screening substantially. Conversely, Hawaii, which
64

We read the editorial comment on our work with great interest
and thank the authors for launching an important discussion regarding the underlying reasons for heterogeneous adoption of
prostate-specific antigen (PSA) testing recommendations on a
state-level.
In addition to common “background noise” (ie, external circumstances, which may affect various screening procedures in a
similar way), there are likely many measured and unmeasured determinants of screening. These have come to light more than ever
in a situation when updated recommendations are conflicting,
yet expected to be implemented into daily practice. We believe
that among the many determinants of PSA screening decisions,
2 are particularly noteworthy.
Firstly, sociodemographic characteristics have been shown to
significantly influence screening decisions. This is true on both
the patient1,2 and provider level,3,4 with the latter seeming to have
an overrepresentative effect. In addition, we recently showed that
regional variation is largely race-dependent,5 independent of other
socioeconomic parameters known to affect screening utilization.
Secondly, we have explored the possibility that state-level heterogeneity in implementation of health-care screening policy may,
in part, be explained by an interrelationship of conflicting political philosophies (conservative vs liberal). We recently demonstrated a significant correlation between the change in PSA
screening rates 2012 to 2014 and a state’s level of conservativeness. In politically conservative states according to Gallup U.S.
UROLOGY 112, 2018
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Daily (http://www.gallup.com; accessed April 4, 2016), screening prevalence was unchanged, whereas in the least conservative states there was a significant decline in PSA screening.6
Indeed, approximately one-fourth of the observed variation in
PSA screening trends can be ascribed to a state’s political leaning.
Even if these findings have to be interpreted as preliminary and
hypothesis generating, they suggest an influence of a state’s dominant political ideology on regional health-care screening policy
implementation.
Although future research is necessary to elucidate such potential dependencies, we agree with the editorialist’s final comment.
It is the clinician’s role to provide evidence-based PSA screening recommendations and support decisions that align with a patient’s personal preferences.
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